Report : Asia Pacific Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)

At 6.5% CAGR, the Asia Pacific Pulmonary Arterial Hypertension Market is speculated to be worth US$ 2,236.62 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Asia Pacific pulmonary arterial hypertension market was valued at US$ 1,531.47 million in 2022 and is expected to reach US$ 2,236.62 million by 2028, registering a CAGR of 6.5% from 2022 to 2028. Availability of generics at affordable costs due to growing patent expiration and rising clinical trials for drugs development to treat pulmonary arterial hypertension are the critical factors attributed to the Asia Pacific pulmonary arterial hypertension market expansion.

Patent expiry permits generic drugs to penetrate the market and diversify product offerings. Over the next seven–eight years till 2030, the patented products are expected to go off-patent. This would provide an enormous opportunity for generic formulation companies in the coming years. Many pharma companies are already working to develop the generic version of patented products, finds Care Ratings. After patent expiration, generic versions of drugs can become available. While consumers benefit from low prices, losing patent protection can expose pharmaceutical companies to growing competition. Thus, patent expiration is expected to open up an opportunity for generic drug manufacturers to enter a new market. Thus, the growing patent expiration will offer lucrative opportunities for the Asia Pacific pulmonary arterial hypertension market expansion in the future.

On the contrary, side effects of drugs used for treatment of pulmonary arterial hypertension hurdles the growth of Asia Pacific pulmonary arterial hypertension market.

Based on drugs, the Asia Pacific pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (eras), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. The prostacyclin and prostacyclin analogs segment held 37.9% share of Asia Pacific pulmonary arterial hypertension market in 2022, amassing US$ 580.01 million. It is projected to garner US$  886.64 million by 2028 to expand at 7.3% CAGR during 2022–2028.

Based on type, the Asia Pacific pulmonary arterial hypertension market is bifurcated into branded and generics. The branded segment held 63.1% share of Asia Pacific pulmonary arterial hypertension market in 2022, amassing US$ 965.91 million. It is projected to garner US$ 1,433.85 million by 2028 to expand at 6.8% CAGR during 2022–2028.

Based on route of administration, the Asia Pacific pulmonary arterial hypertension market is segmented into oral, intravenous/ subcutaneous, and inhalational. The oral segment held 41.6% share of Asia Pacific pulmonary arterial hypertension market in 2022, amassing US$ 637.72 million. It is projected to garner US$ 964.99 million by 2028 to expand at 7.1% CAGR during 2022–2028.

Based on distribution channel, the Asia Pacific pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. The hospital pharmacies and clinics segment held 46.4% share of Asia Pacific pulmonary arterial hypertension market in 2022, amassing US$ 710.61 million. It is projected to garner US$  1,074.11 million by 2028 to expand at 7.1% CAGR during 2022–2028.

Based on country, the Asia Pacific pulmonary arterial hypertension market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific.  Our regional analysis states that China captured 27.6% share of Asia Pacific pulmonary arterial hypertension market in 2022. It was assessed at US$ 422.74 million in 2022 and is likely to hit US$ 650.63 million by 2028, exhibiting a CAGR of 7.5% during the forecast period.

Key players profiles in  the Asia Pacific pulmonary arterial hypertension market report are Bayer AG; Gilead Sciences Inc; GSK Plc; Johnson & Johnson; Lupin Ltd; Novartis AG; Pfizer Inc; and Teva Pharmaceutical Industries Ltd, among others.

  • Mar-2022, Pfizer Inc. completed the acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several diseases. Pfizer has completed the acquisition of all outstanding shares, options, and restricted stock units of Arena for $100 per share, in cash, for a total equity value of approximately $6.7 billion. The acquisition was completed by way of a merger in accordance with Delaware law and, Arena became a wholly owned subsidiary of Pfizer.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com

Download Free PDF Brochure